Clinical Trial: A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Study to Evaluate the Ability of the HM74A Agonist GSK256073A to Block Niacin-induced Flushing in Healthy Adult Subjects
Brief Summary: To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin are co-administered as single doses to HVTs.
Detailed Summary:
Sponsor: GlaxoSmithKline
Current Primary Outcome:
- Intensity of reported flushing - visual analogue scale; self reported assessment of flushing [ Time Frame: up to 8 hours post dose ]
- Safety and tolerability of GSK256073A and immediate release niacin [ Time Frame: up to 36 hours post dose ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Standard and Secondary pharmacokinetic endpoints of interest [ Time Frame: up to 36 hours post dose ]
- Pharmacodynamic response [ Time Frame: up to 36 hours post dose ]
- Pharmacodynamic response [ Time Frame: up to 24 hours post dose ]
Original Secondary Outcome: Same as current
Information By: GlaxoSmithKline
Dates:
Date Received: January 23, 2008
Date Started: December 2007
Date Completion:
Last Updated: April 26, 2012
Last Verified: April 2012
